Lilly and Stipple Bio announce oncology deal worth up to $5.9 billion

On November 16, 2026, Eli Lilly announced an oncology research and licensing collaboration with privately held biotech Stipple Bio, valued at up to $5.9 billion.

Stipple will use its Pointillist platform to identify binders for tumor-specific cell-surface sites. Lilly plans to pair those discoveries with its oncology technologies to pursue potential cancer therapies across multiple targets and treatment types.

Lilly gets exclusive worldwide rights to develop and commercialize products arising from the collaboration. Stipple will receive an undisclosed upfront payment and equity investment, plus up to $5.9 billion in potential research, development, and commercial milestone payments and tiered royalties if products reach the market.

The $5.9 billion is a potential total tied to milestones—not a disclosed upfront payment. The companies did not reveal the upfront or equity amounts, or the specific targets and treatment approaches covered.

The deal adds to Lilly’s push to expand its oncology pipeline beyond its major diabetes and obesity medicines. The collaboration’s goal is to target tumors more selectively, potentially improving efficacy while reducing damage to healthy tissue.

Sources:

Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion

Stipple Bio Announces Multi-Target Multi-Modality Oncology

News – Stipple Bio

Stipple Bio, Eli Lilly Ink $5.9B Precision Oncology Research, Licensing Pact

Lilly signs $5.9B deal with Stipple to unlock oncology targets

Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio - Pharmaceutical Technology

Lilly pens another deal, inking up to $5.9B oncology pact with Stipple

Eli Lilly, Stipple Bio Sign Oncology Research Deal

Stipple's epitope-targeting platform lands up to $5.9B Lilly deal

Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies - Eli Lilly (NYSE:LLY)

Lilly strikes up to $5.9B cancer deal with Stipple Bio

Lilly inks oncology licensing deal worth up to $5.9B with Stipple Bio

Lilly signs oncology research deal with Stipple Bio worth up to $5.9 billion

Stipple Bio Announces Multi-Target Multi-Modality ...

Lilly signs oncology research deal with Stipple Bio worth up to $5.9 billion